Pioneering healthtech startup, Wandercraft, has just announced €40 million of new funding to continue advancing dynamic robotics and exoskeleton technology.
The series C round was led by the US fund Quadrant Management, joined by existing investor Bpifrance and new participants MACSF, Malakoff Humanis, AG2R La Mondiale, Mutuelles Impact and Sofiouest. Other existing investors Xange, Eurazeo, LBO France and Cemag Invest also participated in the round.
Matthieu Masselin CEO of Wandercraft said: “With the support of patients, medical professionals and the DeepTech community, Wandercraft’s team has created a unique technology that improves rehabilitation care and will soon enable people in wheelchairs to regain autonomy and improve their everyday health.”
Founded in 2012, Wandercraft was established with a mission of enabling mobility for all by a group of engineers who refused to accept the status quo of wheelchair use and create a better solution. Wandercraft builds autonomous walking exoskeletons. Its first version, Atalante, was commercialized in 2019 and is used by rehabilitation and neurological hospitals in Europe and North America.
Wandercraft is now developing a personal version of the exoskeleton for outdoor and home use. It will enable people with reduced mobility to regain autonomy in their daily activities and improve their health, both at home and elsewhere.
This new funding will help the company continue developing and then launch the personal exoskeleton as well as accelerate the deployment of Atalante in the US.
Alan Quasha, Chairman and CEO of Quadrant Management, commented: “Wandercraft has developed the world’s most advanced technology in walk robotics and markets the first self-stabilized exoskeletons. We share Wandercraft’s ambition to provide a new solution for mobility, and to improve the health of millions of people using wheelchairs. We believe that they will transform mobility and become the leading player in the market.”